Beneva's 2025 Health Trends and Insights
Medical innovation highlights importance of sound group insurance plan management
QUEBEC CITY, April 15, 2025 /CNW/ - Beneva's 2025 Health Trends and Insights report, Connecting the Dots, points out the fact that although medical innovation is paving the way toward breakthrough treatments for obesity, Type 2 diabetes, Inflammatory Bowel Disease and cancer, it is also applying pressure on the financial sustainability of group insurance plans.
The challenge for insurers is to control plan costs without compromising insureds' access to care.
2025 Health Trends and Insights
Rise of anti-obesity drugs: Since entering the Canadian market in May 2024, Beneva has reimbursed $10.2 million in claims for Wegovy. This amount could exceed $25 million in 2025.
Proliferation of diabetes: The number of people suffering from Type 2 diabetes has grown steadily by almost 5% per year from 2015 to 2024. The average yearly claim cost of diabetics is nearly 3.7 times more than for non-diabetics ($3,300 compared to $900).
Necessity of biosimilars: Remicade, the brand-name prescription medication used to treat Crohn's Disease, was the most in-demand drug in 2020. In 2024, it fell to 23rd on the list with the arrival of Renflexis, its biosimilar equivalent.
Game-changing oncological advances: From 2014 to 2024, total spending on cancer therapies almost quadrupled and the average cost of treatment almost doubled from $7,800 to $14,700 over the same period.
To find out more, read Connecting The Dots.
Ensuring the sustainability of group insurance plans
For Beneva, striking a balancing between access to care, cost management and innovation is crucial.
"As a mutual insurance company, we want to offer our members peace of mind and optimize their access to healthcare. Beneva's success lies in keeping plan costs as low as feasibly possible. According to our experts, long-term plan sustainability can be achieved through an optimized drug management strategy as well as through our integrated and comprehensive health and wellness offer for plan sponsors," said Éric Trudel, Executive Vice-President of Group Insurance at Beneva.
In 2024, to better inform its members and partners, Beneva's experts began publishing an annual report on the latest health trends affecting the group insurance industry.
About Beneva
Created by the coming together of La Capitale and SSQ Insurance, Beneva is the largest insurance mutual in Canada with more than 3.5 million members and customers. Beneva employs over 5,500 dedicated employees: people looking out for people. Its human approach is rooted in mutualist values that are shared by its employees. With $25.1 billion in assets, Beneva positions itself as a major player in the insurance and financial services industry. Its head office is located in Quebec City. For more information, visit beneva.ca.
SOURCE Beneva
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/15/c7374.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Former MuchMusic VJ Juliette Powell, 54, died 'unexpectedly': What to know about bacterial meningitis
Juliette Powell, a former MuchMusic VJ and author, has died. The 54-year-old, who appeared on Canadian television in the '90s as a host of Electric Circus and French Kiss died on June 3 after a brief illness. According to her obituary, Powell, who was born in the U.S. but raised in Montréal, "succumbed unexpectedly" due to acute bacterial meningitis. "Juliette had a magical way of drawing people in with her infectious enthusiasm, and her brilliant intelligence and gorgeous smile lit up every room she ever entered," reads her obituary. "Her loss is devastating and she will be deeply, painfully missed by so many." This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. In 1989, Powell became the first Black woman to be crowned Miss Canada. She joined MusiquePlus as a VJ in 1992 before going on to join MuchMusic in 1996. Eventually, she transitioned out of music and became a business reporter for CablePulse24. Following her career in television, she authored several books including The AI Dilemma: 7 Principles for Responsible Technology in 2023. So, what is bacterial meningitis and what are the signs and symptoms? Read on to learn everything you need to know about the condition. Meningitis is the inflammation of the lining around the brain and spinal cord membranes, typically caused by an infection, bacteria or sometimes fungi. According to Meningitis Foundation Canada, untreated bacterial meningitis is a "medical emergency" and can be "fatal in a few hours." Those who do recover can have permanent disabilities, such as brain damage, hearing loss and learning disabilities. The condition usually spreads through close contact to bacteria or virus, such as cold or flu germs. As such, sneezing, coughing, kissing and close physical contact can cause the germs to spread. Because it is difficult to stop the transmission of bacteria, prevention is essential. Bacterial meningitis is diagnosed by a medical professional after analyzing a sample of spinal fluid from the patient. This condition can often be mistaken for another life-threatening illness, sepsis, which is the body's extreme response to infection. Sepsis happens when an infection triggers a chain reaction throughout your body. Without timely treatment, sepsis can quickly lead to tissue damage, organ failure and death. That the timing of bacterial meningitis symptoms can vary widely. Some people can get sick within a few hours of contracting the condition, while it may take others one to three days to show symptoms. Typically, early symptoms, occurring within the first six hours, include fever, headache, irritability, nausea and vomiting. Later symptoms occurring within six to 12 hours involve fever, muscle aches, leg pain and pale skin. After 12 hours, symptoms usually include cold hands and feet, stiff neck or neck pain, rash, confusion or delirium and decreasing responsiveness. If you or someone you know is experiencing any of the above symptoms, seek medical attention immediately. Certain risk factors can increase a person's risk for getting bacterial meningitis. The risk factors include: Age: Babies or young children are more likely to contract bacterial meningitis due to their weakened immune systems. That said, people of any age can develop the condition. Group settings: Meningitis tends to spread where large groups of people gather or live in close quarters, such as college dorms or music festivals. Certain medical conditions: Some medical conditions, medications or surgical procedures put people at increased risk for contracting bacterial meningitis. For example, having an HIV infection or not having a spleen can increase a person's risk for the condition. There are many ways to help prevent bacterial meningitis. Firstly, different vaccines can help protect against certain types of bacterial meningitis. There are vaccines for four types of bacteria that can cause the condition. Additionally, maintaining good health, washing your hands often, staying home when you're sick and having a strong immune system can protect us from most causes. Oftentimes we carry meningitis germs with no ill effects. However, if your immune system is compromised due to cancer treatments, HIV, organ transplants, infection or other serious health issues, speak with your doctor about how to help protect against meningitis. Lastly, seeking medical attention as soon as symptoms appear is essential. Moreover, as the condition is contagious, if you've been around someone who has it, call your healthcare provider to discuss how to keep from getting sick.
Yahoo
2 hours ago
- Yahoo
2 Weight Loss Drug Stocks That Are Screaming Buys in June
Novo Nordisk and Eli Lilly have most of the GLP-1 drug market to themselves. Based on current pipelines, this state of affairs could continue. Both stocks are attractively priced at the moment. 10 stocks we like better than Novo Nordisk › Is there a hotter trend in healthcare than weight loss drugs? Probably not. Research from Morgan Stanley suggests that sales of weight loss drugs will soar from an estimated $15 billion last year to as much as $150 billion by 2035. That would be a tenfold increase in just over a decade. Most current medications for weight loss are GLP-1 agonists, which suppress patients' appetites by slowing digestion and making them feel full. Two companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), currently dominate this area, together accounting for an estimated 97% of the market share. Can they can stay atop this fast-growing industry? Here's what I found -- and why they could both be screaming buys right now in June 2025. Whenever an opportunity exhibits such rapid growth, it will inevitably attract competition. Indeed, numerous companies are currently developing weight loss drugs. However, it's quite a leap to assume that Novo Nordisk, with 62% of the GLP-1 market, and Eli Lilly with another 35%, will easily cede their market share to new products. First and foremost, drug development is a challenging process that undergoes rigorous regulatory testing. Many of the drugs in development today will ultimately fail to reach the market. In April, industry heavyweight Pfizer abandoned development of its oral weight loss drug danuglipron, after it may have caused a liver injury in a patient during a clinical trial. Weight loss drugs that do make it to market must then actually compete with what patients already use. That boils down to more than price: Efficacy, side effects, and prescribers' comfort levels with products all make a difference in how these treatments ultimately sell. The weight loss opportunity is currently in its early innings. The leading drugs -- Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound -- are injected, require refrigeration, and remain expensive for patients. Upcoming drugs will include more convenient oral pills; some could be cheaper to produce, and thus could be sold at lower prices. Naturally, Novo Nordisk and Eli Lilly have remained active in order to stay atop the market. Novo Nordisk could soon have an oral GLP-1 agonist for sale; it has filed an application for approval of an oral version of Wegovy. The company hopes to receive a nod by the end of this year. Additionally, its candidate CagriSema, a potential successor to Wegovy, is working through phase 3 trials. At this rate, CagriSema could arrive sometime next year. Eli Lilly is also very active. Its experimental oral weight loss drug, orforglipron, has performed well in phase 3 studies. It could be the first small-molecule drug to hit the market; small-molecule drugs are easier and cheaper to manufacture. Its next-generation injectable therapy, retatrutide, is innovative in that it targets three separate hormones related to hunger. Retatrutide is also currently in phase 3 studies, and could arrive in 2027 if all goes well. Boehringer Ingelheim's survodutide, an injected therapy that could arrive in 2027, is arguably the only potential near-term competition worth noting. There aren't any other immediate threats to Novo Nordisk and Eli Lilly's dominance. The next hopeful, MariTide from Amgen, only begins phase 3 studies in March; if approved, its estimated market arrival would be in 2028. Barring something unexpected, Novo Nordisk and Eli Lilly appear well positioned to capture much of that explosive growth in the weight loss market over the coming years. The question is, which industry giant will do better? Wall Street is currently placing its money on Eli Lilly, as evidenced by the stock's significant valuation premium. Shares trade at a price-to-earnings (P/E) ratio of 62, versus just 22 for Novo Nordisk. Novo Nordisk's CagriSema has struggled to outperform existing treatments in clinical trials, while Eli Lilly's orforglipron has performed well. However, how patients choose treatments involves several factors, so it's not a sure thing that Eli Lilly will capture all this market share from Novo Nordisk. The best solution? Own both. One way to value them is by their PEG ratios, which weigh the stocks' valuations against the companies' expected growth rates: Novo Nordisk PEG ratio: 1.5 Eli Lilly PEG ratio: 1.9 Both companies are reasonably priced for their expected long-term earnings growth, currently 14% annualized for Novo Nordisk and 32% annualized for Eli Lilly. Of course, that could play out differently, but it's all the more reason to own both stocks. One way or another, these two companies will likely split the upside in the weight loss drug market. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Weight Loss Drug Stocks That Are Screaming Buys in June was originally published by The Motley Fool
Newsweek
4 hours ago
- Newsweek
Map Shows 2 States Where Children Warned of Breathing Difficulties
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Air quality alerts continued on Tuesday, with children in two states being warned of "breathing difficulties" if they are exposed to poor air quality. Weather conditions such as light winds and higher temperatures are causing smoke from Canadian wildfires to settle in Ohio, pushing air quality into the unhealthy range, National Weather Service (NWS) observing program leader Brian Mitchell told Newsweek. Why It Matters Smoke from Canadian wildfires prompted widespread air quality alerts across the Upper Midwest, Great Lakes, and Northeast regions over the past few weeks. As of Tuesday, most of the smoke has moved out of the region. However, air quality alerts remain in parts of Ohio and Arizona for fine particulate matter and ozone pollution, respectively. The Air Quality Index (AQI) is expected to be Unhealthy for Sensitive Groups, which includes children and the elderly, in the affected regions. What to Know When inhaled, particles can lodge deep in the lungs and trigger inflammation, while ozone irritates the respiratory system and can exacerbate asthma. Children are particularly vulnerable to the impacts because of their developing respiratory systems and tendency to spend more time outdoors. In Ohio, the air quality alert was issued by the Northeast Ohio Areawide Coordinating Agency and warns of ground-level fine particles affecting the air quality in Ashtabula, Cuyahoga, Geauga, Lake, Lorain, Medina, Portage and Summit Counties. A stock image shows a child coughing while outside. A stock image shows a child coughing while outside. AaronAmat/Getty "Air quality levels will be unhealthy for sensitive groups during this period. If you are in the sensitive groups category of children, the elderly and those with breathing difficulties, please monitor your outdoor activity and check air quality readings at In Arizona, an Ozone High Pollution Advisory was in place for Maricopa County, including more than a million people who live in the Phoenix metropolitan area. Sunlight can contribute to higher ozone levels, making these alerts more common in the summertime. "This means that forecast weather conditions combined with existing ozone levels are expected to result in local maximum 8-hour ozone concentrations that pose a health risk. Adverse health effects increase as air quality deteriorates," the alert said. "Ozone is an air contaminant which can cause breathing difficulties for children, older adults, as well as persons with respiratory problems. A decrease in physical activity is recommended." In both states, people were urged to avoid worsening air quality levels by driving less, not idling in their vehicles, refilling their gas tanks after sunset, and waiting to mow the lawn. An air quality alert also was in place for parts of Michigan, although people in that state were not warned of breathing difficulties. What People Are Saying Air quality alert in Arizona: "You are urged to car pool, telecommute or use mass transit. The use of gasoline-powered equipment should be reduced or done late in the day." Air quality alert for Michigan: "Surface temperatures well into the 80s, ample sunlight, and west-southwest winds will create a conducive environment for Ozone development along the Lake Michigan shoreline. Residual wildfire smoke in the region may also enhance Ozone development over Lake Michigan." What Happens Next Both alerts are in place throughout Tuesday. More air quality alerts could be issued as smoke is expected to return on Wednesday.
